Sexual dysfunction is difficulty experienced by an individual or a couple during any stage of a normal sexual activity, including physical pleasure, desire, preference, arousal or orgasm.
The increasing prevalence of chronic diseases is one of the key factors that will drive the growth of the market during the forecast period. Women suffering from chronic health conditions such as diabetes may also be diagnosed with sexual dysfunction. Clinical indications, including hypertension, obesity, metabolic syndrome, and atherogenic dyslipidemia, of chronic conditions such as diabetes, are the risk factors for sexual dysfunctions in women. The rising prevalence of chronic health conditions in women will increase the incidence of female sexual dysfunctions. This will provide considerable growth opportunities to market participants.

Mental health conditions such as depression are being recognized as critical health issues mostly among women. As a result, many pharmaceutical companies are releasing drugs and therapies to treat these conditions leading to an increase in the consumption of antidepressants, antipsychotics, and antiepileptics. Moreover, there is also an increase in the consumption of contraceptives. These drugs cause sexual dysfunctions in women.

Market Analysis and Insights: Global Female Sexual Dysfunction Treatment Market
The global Female Sexual Dysfunction Treatment market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Female Sexual Dysfunction Treatment market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Female Sexual Dysfunction Treatment market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Female Sexual Dysfunction Treatment market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Female Sexual Dysfunction Treatment market.

Global Female Sexual Dysfunction Treatment Scope and Market Size
Female Sexual Dysfunction Treatment market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Female Sexual Dysfunction Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Non-hormonal Therapy
Hormonal Therapy

Segment by Application
Sexual Desire Disorders
Sexual Arousal Disorders
Orgasm Disorders
Sexual Pain Disorders
Post-orgasmic Diseases
Pelvic Floor Dysfunction
Other

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
AMAG Pharmaceuticals Inc.
Duchesnay Inc.
Emotional Brain BV
Novo Nordisk AS
Sprout Pharmaceuticals Inc.